Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study"

Circulation

Volumn 125, Issue 8, 2012, Pages

  Forfia, Paul R ^a   Borlaug, Barry A ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V; SILDENAFIL;

CENTRAL VENOUS PRESSURE; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LETTER; LUNG WEDGE PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASODILATATION;

FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; STROKE VOLUME; SULFONES;

EID: 84857935168     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.064584     Document Type: Letter

References (4)

1. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-174.
2. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-451.
3. Prasanna V, Raina A, Arkles J, Opotowsky A, Kawut S, Smith A, Forfia P. Echo-Doppler scoring system identifies 'proportionate' and 'disproportionate' pulmonary hypertension in patients with chronic left heart disease and respiratory disease. Am J Respir Crit Care Med. 2011;183:A2294.
4. Drazner MH, Prasad A, Ayers C, Markham DW, Hastings J, Bhella PS, Shibata S, Levine BD. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail. 2010;3:202-206.